Michael Cohen-Wolkowiez

Husband, dad, pediatrician, clinical trialist, pharmacologist, mentor

[Michael Cohen-Wolkowiez @mickycwMD]

@US_FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare #autoimmune disorder #LEMS #neuromuscular https://t.co/BOFq8tNabD highlights power of PK/PD modeling and simulation for pediatric drug development @DCRINews

[Michael Cohen-Wolkowiez @mickycwMD]

Excited to partner with Neogia to bring new tech to humans via our early phase unit https://t.co/4x0grDX1so @DCRINews @DukeMedSchool

[Neogia @NeogiaTech]

Following the announcement of the nominees, Neogia and its partners Duke Clinical Research Institute and Analog Devices are participating today, in the ceremony of the Galien #Medstartup USA Award at #NewYork #USA , for the solution Motio HW.
#PrixGalien #NeogiaTech

[Michael Cohen-Wolkowiez @mickycwMD]

Credit goes to all the staff at DEPRU for making this happen https://t.co/DUUaavBmSZ

[Duke Clinical Research Institute @DCRINews]

DCRI begins early-stage clinical trial of #antimalarial drug. The new study -- sponsored by the NIAID and led by DCRI's @mickycwMD -- is testing an investigational drug called DM1157 https://t.co/6Bj9Eu90i2 @NIAIDNews @NIH

[Michael Cohen-Wolkowiez @mickycwMD]

@Pharmaforkids The importance of the ‘right dose’

[Michael Cohen-Wolkowiez @mickycwMD]

Kudos to our outstanding and dedicated staff that is enrolling like crazy for Project Baseline https://t.co/DUUaavBmSZ @DCRINews https://t.co/JRC28Qlf8O

[Duke University School of Medicine @DukeMedSchool]

1-year mark for Project Baseline study. Ambitious effort to develop well-defined “baseline” of health, and rich data platform to better understand health & disease and transitions between them. Duke, Verily, Stanford Med, Google collaborate. @Duke_CTSI https://t.co/qURoB6RyEA

[Michael Cohen-Wolkowiez @mickycwMD]

Also think @Book_Harvest https://t.co/l6ROQWKg5z

[Michael Cohen-Wolkowiez @mickycwMD]

This is such a powerful program - how do we increase the pipeline of underrepresented minority scientists if we don’t start early? So much talk about diversity inclusion and not enough action. STAR is action. @PediatricTrials @PedsDanny @DukeMedSchool @DCRINews https://t.co/op8VIEDZZv

[Michael Cohen-Wolkowiez @mickycwMD]

Neonatal studies are tough, but dedicated investigators and families together can do it - @US_FDA recognized the value and need - read last bullet @PediatricTrials @NICHD_NIH @EMA_News

[Michael Cohen-Wolkowiez @mickycwMD]

Looking forward to expanding partnerships between @PediatricTrials and @KidsCANtrials https://t.co/Vt8iuBIeVr

[Michael Cohen-Wolkowiez @mickycwMD]

Grateful to be a part of this group of humans @PediatricTrials @PedsDanny talk about accelerating pediatric drug development with a fully established peds network @US_FDA @EMA_News @DukeMedSchool https://t.co/EHDItaCjq4

[Duke Clinical Research Institute @DCRINews]

DCRI’s Pediatric Trials Network (PTN) team has been awarded $96 million by @NICHD_NIH to design and lead #pediatric trials over the next eight years. https://t.co/hyozW8R8zR @PediatricTrials @PedsDanny @mickycwMD

[Michael Cohen-Wolkowiez @mickycwMD]

Privileged to be @EMA_News discussing the future of antibiotic development in children with @US_FDA where @PediatricTrials recognized for moving the needle

[Michael Cohen-Wolkowiez @mickycwMD]

Agree @califf001 heavy publication bias for phase 1 even outside of oncology https://t.co/DUUaavBmSZ @NEJM https://t.co/s9f5UCzdX8

[Michael Cohen-Wolkowiez @mickycwMD]

Great review - incorporating maturation of PD endpoints will be key - we can tackle this @micyrn @PediatricTrials https://t.co/EVVxYIdYdb

[MICYRN @micyrn]

Useful pharmacodynamic endpoints in children: selection, measurement, and next steps: https://t.co/VHGrZzFdUE

[Michael Cohen-Wolkowiez @mickycwMD]

Implementing new tech in early phase research - ready to launch Hu.BITS at Duke: human biomarker discovery and tech eval study https://t.co/DUUaavBmSZ - new era, new signals of drug effect @DCRINews https://t.co/5U4Bqtewx3

[Duke Clinical Research Institute @DCRINews]

Clinical Research Day, co-hosted by @DukeMedSchool @dukegme & DCRI, highlighted role of new technologies in bldg partnerships: "One of the most important drivers for advancing clinical research is the use of new technologies," said @texhern https://t.co/1qGZlBXh1G

[Michael Cohen-Wolkowiez @mickycwMD]

Such a need for these absorption studies - we can start with adults at https://t.co/DUUaavBmSZ and then move to children, pregnant women and older adults - not many people thinking about these risks https://t.co/7VXkabKZnY

[Michael Cohen-Wolkowiez @mickycwMD]

Lessons learned from pediatric trials can accelerate trials in pregnant women - such a need @PediatricTrials https://t.co/PNc7u4cbfe

[MICYRN @micyrn]

Pregnant Women Need Inclusion in Research, Task Force Says https://t.co/rYJ6fwroav

[Michael Cohen-Wolkowiez @mickycwMD]

This is such a big deal for @PediatricTrials and partners such as @RCHMelbourne and @kids_research - easy to write in a tweet but a lot of effort to make it a reality - a step closer to a global peds clin trials network https://t.co/nXDb4fBbuN

[Michael Cohen-Wolkowiez @mickycwMD]

Anybody wonder the potential toxicities of chronic chemical application of sunscreen in children? Skin cancer prevention benefit is clear - but are we overlooking potential side effects? Wonder what @califf001 thinks @PediatricTrials https://t.co/BVNyhH3hJg

[Michael Cohen-Wolkowiez @mickycwMD]

Agree with @califf001 and @RossMcKinneyMD - substantial problem if folks have the illusion that phase 1 provides sufficient evidence for patient treatment - especially because at least half of the doses at this phase are subtherapeutic https://t.co/DUUaavBmSZ https://t.co/wwDrlC0gt3

[Michael Cohen-Wolkowiez @mickycwMD]

Should we beta-test a ‘look up’ pilot to have some smartphone breaks @texhern ? https://t.co/fNm5TNmJq2

[Adrian “WE NEED RCTS!” Hernandez @texhern]

Wow— we are way engaged with our #Smartphone @DukeMedSchool #dukeclinicalreseach